AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30958543 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV
Number of subjects: 1200
Study 30958543 — intervention group
Group type: COMPARATOR
Intervention: IPV
Number of subjects: 1200
Study 28295143 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired orthostatic blood pressure recovery (OH(40))
Number of subjects: 4127
Study 28295143 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic hypotension (OH)
Number of subjects: 4127
Study 28295143 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial orthostatic hypotension (IOH)
Number of subjects: 4127
Study 26252749 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg
Number of subjects: 13
Study 26252749 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 2 g
Number of subjects: 13
Study 23718900 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg vinorelbine, taken orally three times a week
Number of subjects: 73
Study 23718900 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg vinorelbine, taken orally three times a week
Number of subjects: 73
Study 23718900 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg vinorelbine, taken orally three times a week
Number of subjects: 73
Study 23718900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-treatment blood concentrations of FGF2 and IL8
Number of subjects: 73
Study 23718900 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of TEK gene transcript
Number of subjects: 73
Study 21395901 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique (group 1)
Number of subjects: 175
Study 21395901 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (group 2)
Number of subjects: 175
Study 19411056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education and gardening (NE+G)
Number of subjects: 115
Study 19411056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education only (NE)
Number of subjects: 115
Study 19411056 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 115
Study 17539707 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using a laser source with a wavelength of 690 nm associated with a phenothiazine photosensitizer
Number of subjects: 10
Study 17539707 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) with hand instruments
Number of subjects: 10
Study 15458995 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression information website (BluePages)
Number of subjects: 525
Study 15458995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural skills training website (MoodGYM)
Number of subjects: 525
Study 15458995 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 525
Study 11596587 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 198
Study 11596587 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 198
Study 10063958 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management (1994)
Number of subjects: 280
Study 10063958 — intervention group
Group type: COMPARATOR
Intervention: No case management (1990)
Number of subjects: 280
Study 7917929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen, 20 mg daily
Number of subjects: 254
Study 7917929 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen and prednisolone, 7.5 mg daily
Number of subjects: 254
Study 3395544 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 20
Study 3395544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31978933 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (0.75, 1.5 mg/kg)
Number of subjects: 31
Study 31978933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20 IU)
Number of subjects: 31
Study 31978933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31002539 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole
Number of subjects: 0
Study 31002539 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 0
Study 31002539 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 0
Study 28263288 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza vaccine (MF59)
Number of subjects: 73
Study 28263288 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted influenza vaccine
Number of subjects: 73
Study 26814087 — intervention group
Group type: EXPERIMENTAL
Intervention: NI15 combined with 30% ASIR
Number of subjects: 200
Study 26814087 — intervention group
Group type: EXPERIMENTAL
Intervention: NI25 combined with 40% ASIR
Number of subjects: 200
Study 26814087 — intervention group
Group type: EXPERIMENTAL
Intervention: NI30 combined with 50% ASIR
Number of subjects: 200
Study 26814087 — intervention group
Group type: EXPERIMENTAL
Intervention: NI35 combined with 60% ASIR
Number of subjects: 200
Study 26814087 — intervention group
Group type: COMPARATOR
Intervention: Standard dose group (Group A)
Number of subjects: 200
Study 22575988 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine (in patients with heart rate ≥75 bpm)
Number of subjects: 0
Study 22575988 — intervention group
Group type: COMPARATOR
Intervention: ivabradine (in patients with heart rate <75 bpm)
Number of subjects: 0
Study 21527664 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 20
Study 21527664 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 17114331 — intervention group
Group type: EXPERIMENTAL
Intervention: Consider This Internet-based program (Australia)
Number of subjects: 3311
Study 17114331 — intervention group
Group type: EXPERIMENTAL
Intervention: Consider This Internet-based program (United States)
Number of subjects: 3311
Study 16541481 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 714
Study 15071259 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation Clinic Service (ACS)
Number of subjects: 1165
Study 15071259 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1165
Study 15071259 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ACS vs Usual care
Number of subjects: 1165
Study 10928667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin-C (0.02%)
Number of subjects: 37
Study 10928667 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival autograft
Number of subjects: 37
Study 8822656 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oxytocin (2.5 mU/minute initial dose, increments of 2.5 mU/minute)
Number of subjects: 179
Study 8822656 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxytocin (1.25 mU/minute initial dose, increments of 1.25 mU/minute)
Number of subjects: 179
Study 1415400 — intervention group
Group type: EXPERIMENTAL
Intervention: One-layer closure with continuous locking No. 1 chromic suture
Number of subjects: 906
Study 1415400 — intervention group
Group type: COMPARATOR
Intervention: Two-layer closure with continuous No. 1 chromic suture
Number of subjects: 906
Study 1415400 — intervention group
Group type: EXPERIMENTAL
Intervention: One-layer closure
Number of subjects: 906
Study 1415400 — intervention group
Group type: COMPARATOR
Intervention: Two-layer closure
Number of subjects: 906
Study 4061901 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg lidocaine intravenously
Number of subjects: 208
Study 4061901 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg lidocaine intravenously
Number of subjects: 208
Study 4061901 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg lidocaine intravenously
Number of subjects: 208
Study 4061901 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg lidocaine intravenously
Number of subjects: 208
Study 4061901 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg lidocaine intravenously
Number of subjects: 208
Study 4061901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 31270984 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR CT measurements
Number of subjects: 210
Study 31270984 — intervention group
Group type: COMPARATOR
Intervention: Axial measurements
Number of subjects: 210
Study 31270984 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR diameter
Number of subjects: 210
Study 31270984 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D measurements
Number of subjects: 210
Study 28455318 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) within 7 days after symptom onset
Number of subjects: 4138
Study 28455318 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) within 7 days after symptom onset
Number of subjects: 4138
Study 28455318 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) after 1 week
Number of subjects: 4138
Study 28455318 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) after 1 week
Number of subjects: 4138
Study 25612603 — intervention group
Group type: EXPERIMENTAL
Intervention: RATG (0.5 mg/kg/day)
Number of subjects: 16
Study 25612603 — intervention group
Group type: COMPARATOR
Intervention: RATG plus basiliximab (20 mg on days 0 and 4)
Number of subjects: 16
Study 25612603 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA therapy
Number of subjects: 16
Study 25612603 — intervention group
Group type: COMPARATOR
Intervention: MMF therapy
Number of subjects: 16
Study 24321183 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 117
Study 24321183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 21786039 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate (APC) added to local autograft plus TCP/HA
Number of subjects: 107
Study 21786039 — intervention group
Group type: COMPARATOR
Intervention: Control group without APC addition
Number of subjects: 107
Study 19160730 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17524873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valgancyclovir for 2 weeks (VAL2w)
Number of subjects: 110
Study 17524873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valgancyclovir for 3 months (VAL3m)
Number of subjects: 110
Study 17524873 — intervention group
Group type: COMPARATOR
Intervention: Intravenous gancyclovir for 2 weeks (GAN)
Number of subjects: 110
Study 15337799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregovomab
Number of subjects: 145
Study 15337799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 15337799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oregovomab (SFLT population)
Number of subjects: 145
Study 15337799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SFLT population)
Number of subjects: 145
Study 15337799 — intervention group
Group type: COMPARATOR
Intervention: Oregovomab and Placebo
Number of subjects: 145
Study 15337799 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 145
Study 12559484 — intervention group
Group type: EXPERIMENTAL
Intervention: COMs
Number of subjects: 66
Study 12559484 — intervention group
Group type: COMPARATOR
Intervention: ANXs
Number of subjects: 66
Study 12559484 — intervention group
Group type: COMPARATOR
Intervention: NACs
Number of subjects: 66
Study 12559484 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (within COMs)
Number of subjects: 66
Study 12559484 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (within COMs)
Number of subjects: 66
Study 9526931 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral diazepam
Number of subjects: 202
Study 9526931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 11271312 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher oral FK 506 dose (0.19 mg/kg bw per day) in early phase of multicenter trial
Number of subjects: 267
Study 11271312 — intervention group
Group type: COMPARATOR
Intervention: Lower oral FK 506 dose (0.14 mg/kg bw per day) in late phase of multicenter trial
Number of subjects: 267
Study 11271312 — intervention group
Group type: COMPARATOR
Intervention: Further reduced FK 506 dosage (0.10 mg/kg bw per day or less) in recent single centre treatment
Number of subjects: 267
Study 11271312 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with online FK 506 blood level monitoring
Number of subjects: 267
Study 2459543 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 1 mg intravenous infusion
Number of subjects: 0
Study 2459543 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 3 mg intravenous infusion
Number of subjects: 0
Study 2459543 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg oral solution
Number of subjects: 0
Study 2459543 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 15 mg oral solution
Number of subjects: 0
Study 2459543 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 40 mg oral solution
Number of subjects: 0
Study 2459543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15784645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Control (IC)
Number of subjects: 19
Study 15784645 — intervention group
Group type: COMPARATOR
Intervention: Conventional Control (CC)
Number of subjects: 19
Study 31689342 — intervention group
Group type: EXPERIMENTAL
Intervention: Kihon Checklist (KC)
Number of subjects: 243
Study 31689342 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported Edmonton Frail Scale (REFS)
Number of subjects: 243
Study 31689342 — intervention group
Group type: COMPARATOR
Intervention: Fried's Frailty Phenotype (FP)
Number of subjects: 243
Study 31689342 — intervention group
Group type: COMPARATOR
Intervention: Adelaide Frailty Index (AFI)
Number of subjects: 243
Study 30942007 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture performed within 3 days after onset (Group A)
Number of subjects: 120
Study 30942007 — intervention group
Group type: COMPARATOR
Intervention: Oral mecobalamin dispersible tablets and multivitamin B tablets within 3 days after onset, acupuncture started from the 4th day (Group B)
Number of subjects: 120
Study 30942007 — intervention group
Group type: COMPARATOR
Intervention: Oral mecobalamin dispersable tablets and multivitamin B tablets within 5 days after onset, acupuncture from the 6th day (Group C)
Number of subjects: 120
Study 30942007 — intervention group
Group type: COMPARATOR
Intervention: Oral mecobalamin dispersable tablets and multivitamin B tablets within 7 days after onset, acupuncture from the 8th day (Group D)
Number of subjects: 120
Study 27053195 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-selected music to support walking with guidance from a music therapist
Number of subjects: 56
Study 27053195 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (Control)
Number of subjects: 56
Study 27053195 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-selected music
Number of subjects: 56
Study 26852638 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES (neuromuscular electrical stimulation)
Number of subjects: 0
Study 26852638 — intervention group
Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 0
Study 26852638 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 0
Study 23845716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography screening
Number of subjects: 7582
Study 23845716 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive baseline screening result
Number of subjects: 7582
Study 23845716 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate baseline screening result
Number of subjects: 7582
Study 23845716 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative baseline screening result
Number of subjects: 7582
Study 21663717 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative interscalene block with 30 mL of 0.5% ropivacaine
Number of subjects: 53
Study 21663717 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 10 mL of saline solution
Number of subjects: 53
Study 19922568 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 32
Study 19922568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17998689 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: XRT 30 Gy/10 fr/2 weeks + EBBT 8 Gy (2 sessions)
Number of subjects: 45
Study 17998689 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: XRT 30 Gy/10 fr/2 weeks + EBBT 10 Gy (1 session)
Number of subjects: 45
Study 17998689 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm C: EBBT 15 Gy (1 session) without XRT
Number of subjects: 45
Study 12759489 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (0.016 mg/kg/IgE every 4 weeks)
Number of subjects: 35
Study 10970702 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL instruments
Number of subjects: 0
Study 10970702 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique based on ordinal HRQoL data
Number of subjects: 0
Study 9241285 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2000 mg/day)
Number of subjects: 260
Study 9241285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 8284118 — intervention group
Group type: EXPERIMENTAL
Intervention: Proved EV infection
Number of subjects: 57
Study 8284118 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe multisystem disease
Number of subjects: 57
Study 8284118 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of severe disease
Number of subjects: 57
Study 8284118 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 57
Study 8284118 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 57
Study 3549507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy (1% polidocanol, performed twice weekly until varices eradicated)
Number of subjects: 70
Study 3549507 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (twice daily, mean dose 161 +/- 80 mg per day)
Number of subjects: 70
Study 3549507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 70
Study 30028479 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training (gaze direction recognition exercise)
Number of subjects: 40
Study 30028479 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 40
Study 26763851 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium tablets (50‐100 mg per day)
Number of subjects: 244
Study 26763851 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamlodipine besylate tablets (2.5‐5.0 mg per day)
Number of subjects: 244
Study 26763851 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Losartan and Levamlodipine)
Number of subjects: 244
Study 25068412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) using 40 mL ropivacaine 0.5%
Number of subjects: 41
Study 25068412 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (IVFE) 1.5 μg/kg
Number of subjects: 41
Study 22709704 — intervention group
Group type: EXPERIMENTAL
Intervention: Baked beetroot (200 g with ≥500 mg nitrate)
Number of subjects: 11
Study 22709704 — intervention group
Group type: COMPARATOR
Intervention: Cranberry relish (eucaloric placebo)
Number of subjects: 11
Study 20977845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lund concept
Number of subjects: 68
Study 20977845 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 68
Study 18626166 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 60
Study 18626166 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group C)
Number of subjects: 60
Study 18626166 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg and Normal saline (Group C)
Number of subjects: 60
Study 18626166 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 60
Study 15728536 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal compound-free (ACF) medium
Number of subjects: 56
Study 15728536 — intervention group
Group type: EXPERIMENTAL
Intervention: ACF medium combined with poloxamer 188
Number of subjects: 56
Study 15728536 — intervention group
Group type: EXPERIMENTAL
Intervention: ACF medium after 30 days of storage and deswelling in poloxamer 188
Number of subjects: 56
Study 15728536 — intervention group
Group type: EXPERIMENTAL
Intervention: ACF medium alone and combined with poloxamer 188
Number of subjects: 56
Study 15728536 — intervention group
Group type: COMPARATOR
Intervention: Standard commercialized media containing 2% FCS
Number of subjects: 56
Study 12574563 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (2.5, 5, or 10 mg orally twice daily)
Number of subjects: 45
Study 12574563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10473306 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological debriefing plus education
Number of subjects: 157
Study 10473306 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 157
Study 10473306 — intervention group
Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 157
Study 7573996 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine with dextrose
Number of subjects: 8
Study 7573996 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with dextrose
Number of subjects: 8
Study 7573996 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% dextrose-free lidocaine
Number of subjects: 8
Study 1851069 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 6)
Number of subjects: 24
Study 1851069 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective beta-adrenoceptor blockade (propranolol) (n = 6)
Number of subjects: 24
Study 1851069 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective beta-adrenoceptor blockade (n = 6)
Number of subjects: 24
Study 1851069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic blockade (atropine) (n = 6)
Number of subjects: 24
Study 7028085 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol alone followed by epinephrine after 2 weeks
Number of subjects: 16
Study 7028085 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine alone
Number of subjects: 16